| Literature DB >> 35820717 |
Hyun Woo Jeon1, Young-Du Kim1, Sung Bo Sim1, Mi Hyoung Moon2.
Abstract
BACKGROUND: The histological subtype has been introduced in invasive lung adenocarcinoma. The predominant micropapillary and solid subtypes are categorized as high-grade patterns and provide a worse prognosis. However, the prognostic analysis of high-grade patterns has not previously been fully investigated. Thus, this study aimed to investigate the prognostic role of high-grade patterns in pathological stage I lung adenocarcinoma.Entities:
Keywords: adenocarcinoma; lung cancer; micropapillary; solid
Mesh:
Year: 2022 PMID: 35820717 PMCID: PMC9436686 DOI: 10.1111/1759-7714.14578
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.223
FIGURE 1Diagram of patient selection
Baseline patient characteristics
| Characteristic | Total ( |
|---|---|
| Median (range) or n (%) | |
| Age | 64 (36–85) |
| Male | 92 (49.2) |
| Smoking | 69 (36.9) |
| CEA | 2 (0.49–25.83) |
| PET SUVmax | 5 (0.8–17.6) |
| Mixed GGO | 60 (32.1) |
| Lobectomy | 172 (92) |
| Segmentectomy | 15 (8) |
| VATS | 173 (92.5) |
| Thoracotomy | 14 (7.5) |
| Number of dissected LN | 12 (3–47) |
Data are presented as the median (minimum‐maximum) or frequencies and percentages as appropriate.
Abbreviations: CEA, carcinoembryonic antigen; GGO, ground‐glass opacity; LN, lymph node; SUVmax, maximum standardized uptake value; VATS, video‐assisted thoracic surgery.
Pathological data
| Characteristic | Total ( |
|---|---|
| Median (range) or n (%) | |
| Size | 2.3 (0.7–4) |
| Differentiation | |
| Well | 20 (10.7) |
| Moderate | 110 (58.8) |
| Poor | 57 (30.5) |
| Predominant subtype | |
| Acinar | 95 (50.8) |
| Papillary | 20 (10.7) |
| Lepidic | 16 (8.6) |
| MP | 13 (7) |
| Solid | 42 (22.5) |
| MP | 50 (26.7) |
| Solid | 67 (35.8) |
| Distance from the resected margin | 3 (0.5–9.20) |
| LVI | 95 (50.8) |
| BVI | 32 (17.1) |
| VPI | 47 (25.1) |
| pStage IA | 122 (65.2) |
| pStage IB | 65 (34.8) |
| Adjuvant treatment | 13 (6.9) |
Data are presented as the median (minimum‐maximum) or frequencies and percentages as appropriate.
Abbreviations: BVI, blood vessel invasion, LVI, lymphatic vessel invasion, MP, micropapillary; VPI, visceral pleural invasion.
The groups according to the proportion of micropapillary and solid subtype
| MP+/S+ ( | MP+/S− ( | MP−/S+ ( | MPP ( | SP ( |
| |
|---|---|---|---|---|---|---|
| Age | 64 (38–80) | 64(38–82) | 61 (36–85) | 63 (51–80) | 67 (42–82) | 0.633 |
| Male | 12 (57) | 30 (39) | 12 (32.4) | 6 (46.2) | 32 (76.2) | 0.001 |
| Smoking | 8 (38.1) | 20 (26) | 15 (40.5) | 4 (30.8) | 22 (52.4) | 0.055 |
| CEA | 1.76 (0.5–5.59) | 1.71 (0.49–19.15) | 2.69 (0.5–25.83) | 2.28 (0.85–6) | 1.97 (0.5–19.13) | 0.013 |
| SUVmax | 5.47 (2.1–14.55) | 3.5 (0.8–17.6) | 5.8 (1.4–14.6) | 6.5 (2.1–17.4) | 6.82 (1.7–17.14) | < 0.001 |
| Mixed GGO | 5 (23.8) | 38 (49.4) | 10 (27) | 2 (15.4) | 5 (11.9) | < 0.001 |
| Lobectomy | 18 (85.7) | 69 (89.6) | 32 (94.1) | 13 (100) | 40 (95.2) | 0.455 |
| Size | 2.5 (1.5–3.9) | 2 (0.8–4) | 2.45 (0.9–4) | 3.3 (0.7–4) | 2.25 (0.9–4) | 0.011 |
| Differentiation | ||||||
| Well | 0 (0) | 19 (24.7) | 0 (0) | 0 (0) | 1 (2.4) | < 0.001 |
| Poorly | 8 (38.1) | 9 (11.7) | 7 (20.6) | 4 (30.8) | 29 (69.1) | < 0.001 |
| Predominant subtype | ||||||
| Acinar | 15 (71.4) | 51 (66.2) | 29 (85.3) | 0 (0) | 0 (0) | < 0.001 |
| Lepidic | 2 (9.5) | 11 (14.3) | 3 (8.8) | 0 (0) | 0 (0) | 0.078 |
| LVI | 13 (61.9) | 38 (49.4) | 20 (58.8) | 9 (69.2) | 15 (35.7) | 0.109 |
| BVI | 4 (19) | 9 (11.7) | 8 (23.5) | 2 (15.4) | 9 (21.4) | 0.522 |
| VPI | 6 (28.6) | 17 (22.1) | 8 (23.5) | 3 (23.1) | 13 (31) | 0.854 |
| EGFR | 9 (42.9) | 48 (62.3) | 18 (52.9) | 6 (46.2) | 11 (26.2) | 0.005 |
| Stage IB | 10 (47.6) | 15 (19.5) | 15 (44.1) | 9 (61.5) | 17 (40.5) | 0.004 |
| Adjuvant Tx | 1 (4.8) | 2 (2.6) | 1 (2.9) | 3 (23.1) | 6 (14.3) | 0.018 |
Data are presented as the median (minimum‐maximum) or frequencies and percentages as appropriate.
Abbreviations: BVI, blood vessel invasion; CEA, carcinoembryonic antigen; GGO, ground‐glass opacity; LVI, lymphatic vessel invasion; SUVmax, maximum standardized uptake value; VPI, visceral pleural invasion.
Univariate and multivariate analysis for recurrence
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| Smoking | 2.172 | 1.279–3.690 | 0.004 | 2.440 | 1.423–4.184 | 0.001 |
| SUVmax | 1.088 | 1.023–1.156 | 0.007 | |||
| Non‐GGO (solid mass) | 2.696 | 1.355–5.366 | 0.005 | |||
| MPP | 3.413 | 1.665–6.996 | 0.001 | 4.136 | 1.982–8.631 | <0.001 |
| MP | 2.338 | 1.366–4.002 | 0.002 | |||
| BVI | 2.571 | 1.431–4.618 | 0.002 | 2.533 | 1.393–4.607 | 0.002 |
| VPI | 2.208 | 1.279–3.813 | 0.004 | 2.083 | 1.187–3.658 | 0.011 |
Abbreviations: BVI, blood vessel invasion; GGO, ground‐glass opacity; MP, micropapillary; MPP, micropapillary predominant; SUVmax, maximum standardized uptake value; VPI, visceral pleural invasion.
FIGURE 2Survival curve for disease free interval and overall survival
Univariate and multivariate analysis for survival
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| Age | 1.076 | 1.008–1.149 | 0.028 | |||
| Smoking | 4.974 | 1.526–16.215 | 0.008 | 3.752 | 1.117–12.608 | 0.032 |
| SUVmax | 1.128 | 1.002–1.270 | 0.046 | |||
| SP | 4.786 | 1.606–14.264 | 0.005 | 3.308 | 1.071–10.219 | 0.038 |
| VPI | 4.910 | 1.603–15.039 | 0.005 | 4.013 | 1.292–12.468 | 0.016 |
Abbreviations: SUVmax, maximum standardized uptake value; SP, solid predominant; VPI, visceral pleural invasion.